Key Development The chair of the U.S. House Select Committee on the Strategic Competition Between the United States and the... Read more
Tag: #Global Trends
Geopolitical Biopharma Friction: U.S. House Committee Launches National Security Probe into Merck and AbbVie Clinical Trials in China
Key Development The chair of the U.S. House Select Committee on the Strategic Competition Between the United States and the... Read more
Rebounding in the DLBCL Matrix: AbbVie and Genmab Liquidate Monotherapy Setbacks with Landmark Epkinly Combo Victory
Key Development Biopharmaceutical aggregators AbbVie and Genmab have jointly released positive top-line data from their definitive Phase III Epcore DLBCL-4... Read more
Compliance Risk Governance: AstraZeneca Deploys $34 Million to Settle Texas ‘Free Nurses’ Medicaid Kickback Litigation
Key Development Global biopharmaceutical enterprise AstraZeneca has formally agreed to a $34 million financial settlement to resolve a high-profile civil... Read more
The Multi-Billion Orphan Product Transition: Analyzing AstraZeneca’s Phase III Data for Efzimfotase Alfa in Bone Disease
Key Development AstraZeneca, through its core rare disease operational arm Alexion, has officially unveiled detailed high-level data from its pivotal... Read more
Late-Stage Asset Crystallization: Analyzing Ipsen’s $1.7 Billion Strategic Acquisition of Kartos Therapeutics
Key Development Global biopharmaceutical leader Ipsen (Euronext: IPN; ADR: IPSEY) has formally entered into a definitive merger agreement to acquire... Read more
The GLP-1 Warfare in China: Pfizer and Innovent Clear Preliminary National Insurance Hurdles for a Billion-Citizen Market
Key Development China's National Healthcare Security Administration (NHSA) has officially released its updated regulatory ledger showing that next-generation GLP-1 receptor... Read more
Disrupting the Genomics Monopoly: Analyzing Roche’s Strategic Deployment of Axelios to Challenge Illumina
Key Development Swiss healthcare and diagnostics powerhouse Roche has officially launched its next-generation gene sequencing platform, Axelios, marking an aggressive... Read more
Accelerating the Onshoring Wave: FDA Enrolls Eli Lilly and Regeneron in Landmark Real-Time Construction Review Pilot
Key Development The U.S. Food and Drug Administration (FDA) has officially announced the selection of seven pioneering pharmaceutical and biotechnology... Read more









